Blog

Danny Motyka Manufactures Psychedelics for the Masses – Podcast Episode #5

May 25 • 27 min read

On the fifth episode of the Psychedelic Invest Podcast, the CEO of Psygen, Danny Motyka joins to talk about manufacturing psychedelics at scale. During the conversation, host Bruce Eckfedlt asks the hard-hitting questions we all want to know about the development and future accessibility of these medicines. We hope you enjoy it. New episodes of…

PRO: Mind Medicine Earnings Report Breakdown

May 25 • 1 min read

Psychedelic Invest’s very own Adam Tubero digs into Mind Medicine’s ($MNMD) LSD program, Ibogaine, and the company’s Q1 2022 earnings report. Adam explains why his sentiment around MNMD has started to shift lately. Are you bullish or bearish? Leave your comments over on the Psychedelic Invest YouTube channel.

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

May 24 • 4 min read

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development…

Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

May 23 • 4 min read

Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders. Braxia Scientific is pleased to announce that Health Canada has approved the Company’s application to the Special Access Program (‘SAP’) to provide psilocybin-assisted…

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction

May 20 • 4 min read

Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today an update on the previously announced merger with Ei.Ventures Inc. Merger Update Ei has executed a definitive agreement with Mycotopia bringing the two entities together under PSLY.com as the companies move forward with their…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538